TrialA Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Trial details
- Registry ID
- NCT05195528
- Phase
- Phase 3
PHAT
Phathom Pharmaceuticals, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)NCT05195528 | PHAT | Phase 3 | Completed | 2022-11-21Actual |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559 | PHAT | Phase 2 | Active not recruiting | 2026-10Estimated |
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
Trial details
- Registry ID
- NCT06851559
- Phase
- Phase 2
Latest recorded trial changes
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559 · Phathom Pharmaceuticals, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
80 participants (planned)
+ After
95 participants (actual)
Primary completion date changed
− Before
Dec 2026
+ After
Oct 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559 · Phathom Pharmaceuticals, Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting